1. Home
  2. CRON vs TBPH Comparison

CRON vs TBPH Comparison

Compare CRON & TBPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cronos Group Inc.

CRON

Cronos Group Inc.

HOLD

Current Price

$2.61

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Logo Theravance Biopharma Inc.

TBPH

Theravance Biopharma Inc.

HOLD

Current Price

$19.42

Market Cap

1.0B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRON
TBPH
Founded
N/A
2013
Country
Canada
United States
Employees
N/A
N/A
Industry
Medicinal Chemicals and Botanical Products
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.0B
1.0B
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
CRON
TBPH
Price
$2.61
$19.42
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$27.80
AVG Volume (30 Days)
1.4M
368.8K
Earning Date
02-26-2026
03-02-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.09
0.58
Revenue
$132,357,000.00
$80,327,000.00
Revenue This Year
$17.63
$70.90
Revenue Next Year
$30.76
N/A
P/E Ratio
$27.65
$33.66
Revenue Growth
19.00
27.12
52 Week Low
$1.60
$7.90
52 Week High
$3.43
$21.03

Technical Indicators

Market Signals
Indicator
CRON
TBPH
Relative Strength Index (RSI) 49.15 50.55
Support Level $2.57 $18.45
Resistance Level $2.74 $19.71
Average True Range (ATR) 0.09 0.80
MACD 0.00 -0.10
Stochastic Oscillator 58.11 51.63

Price Performance

Historical Comparison
CRON
TBPH

About CRON Cronos Group Inc.

Cronos Group Inc headquartered in Toronto, Canada, cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis primarily to Israel. In the U.S., the company has an option to acquire 5.9% of U.S. multistate operator PharmaCann on a fully diluted basis upon easing of federal prohibition.

About TBPH Theravance Biopharma Inc.

Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).

Share on Social Networks: